• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CTLA-4、PD-1 和 TIM-3 的表达在 MS 患者中主要下调。

CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.

机构信息

Department of Immunology and genetic, Urmia University of Medical Sciences, Urmia, Iran.

Department of Genetics, Urmia University of Medical Sciences, Urmia, Iran.

出版信息

J Neuroimmunol. 2018 Oct 15;323:105-108. doi: 10.1016/j.jneuroim.2018.08.004. Epub 2018 Aug 8.

DOI:10.1016/j.jneuroim.2018.08.004
PMID:30196822
Abstract

Multiple sclerosis (MS), is an autoimmune disorder of central nervous system (CNS) characterized by inflammation and demyelination. Self-tolerance impairment is considered to be induced by a combination of inherited susceptibility and environmental agents. In this work, we demonstrate that a reduction in the comparative expression of well-known inhibitory receptors (i.e., CTLA-4, PD-1, and TIM-3) is importantly linked with MS patients compared to healthy controls. The relative expression of interested genes was performed on peripheral blood mononuclear cells (PBMCs), by using quantitative real time-PCR (qRT-PCR). Our data highlighted the role of inhibitory receptors in the maintenance of immune homeostasis in autoimmune disease.

摘要

多发性硬化症(MS)是一种中枢神经系统(CNS)自身免疫性疾病,其特征为炎症和脱髓鞘。自身耐受的损害被认为是由遗传易感性和环境因素的组合诱导的。在这项工作中,我们证明了与健康对照组相比,多发性硬化症患者中一些众所周知的抑制性受体(即 CTLA-4、PD-1 和 TIM-3)的相对表达显著降低。通过实时定量 PCR(qRT-PCR)在外周血单核细胞(PBMC)中检测感兴趣基因的相对表达。我们的数据强调了抑制性受体在自身免疫性疾病中维持免疫稳态中的作用。

相似文献

1
CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.CTLA-4、PD-1 和 TIM-3 的表达在 MS 患者中主要下调。
J Neuroimmunol. 2018 Oct 15;323:105-108. doi: 10.1016/j.jneuroim.2018.08.004. Epub 2018 Aug 8.
2
Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.血液中抑制性受体的水平:多发性硬化症疾病预后的生物标志物。
Front Immunol. 2019 Apr 30;10:835. doi: 10.3389/fimmu.2019.00835. eCollection 2019.
3
Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.系统性硬化症患者淋巴细胞中共抑制受体 PD-1、TIGIT 和 TIM-3 的表达增加和调节活性改变。
Arthritis Rheumatol. 2018 Apr;70(4):566-577. doi: 10.1002/art.40399. Epub 2018 Mar 7.
4
Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.在神经周围鳞状细胞癌患者的肿瘤内,表达 PD-1、CTLA-4 和 Tim-3 的 CD8 T 细胞频率升高。
PLoS One. 2017 Apr 19;12(4):e0175755. doi: 10.1371/journal.pone.0175755. eCollection 2017.
5
Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.结直肠癌患者 CTLA-4、BTLA、TIM-3 和 LAG-3 分子表达的遗传特征:对诊断和生存结果的影响。
Clin Biochem. 2021 Oct;96:13-18. doi: 10.1016/j.clinbiochem.2021.06.007. Epub 2021 Jul 1.
6
Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.外周T细胞淋巴瘤(PTCL)和NK/T细胞淋巴瘤(NK/T-CL)患者免疫检查点受体的不同异常表达模式。
Asia Pac J Clin Oncol. 2018 Oct;14(5):e252-e258. doi: 10.1111/ajco.12850. Epub 2018 Jan 25.
7
Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.肿瘤浸润 T 细胞在非小细胞肺癌中同时过表达免疫检查点 PD-1、CTLA-4 和 TIM-3 以及 CD200R。
Pathobiology. 2021;88(3):218-227. doi: 10.1159/000511557. Epub 2020 Dec 15.
8
The role of immune regulatory molecules in multiple sclerosis.免疫调节分子在多发性硬化中的作用。
J Neuroimmunol. 2019 Dec 15;337:577061. doi: 10.1016/j.jneuroim.2019.577061. Epub 2019 Sep 5.
9
Differential expression pattern of co-inhibitory molecules on CD4 T cells in uncomplicated versus complicated malaria.CD4 T 细胞共抑制分子在单纯性疟疾与复杂性疟疾中的差异表达模式。
Sci Rep. 2018 Mar 19;8(1):4789. doi: 10.1038/s41598-018-22659-1.
10
Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP.慢性免疫性血小板减少症患者外周血中PD-1和PD-L1的表达较低。
Hematology. 2016 Oct;21(9):552-7. doi: 10.1080/10245332.2016.1155347. Epub 2016 Mar 31.

引用本文的文献

1
Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.胶质母细胞瘤细胞免疫治疗诊断方法的进展:当前趋势与未来方向
Cancer Innov. 2025 Jul 3;4(4):e70018. doi: 10.1002/cai2.70018. eCollection 2025 Aug.
2
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives.TIM-3与PD-1在癌症免疫治疗中的协同作用:机制与展望。
Mol Biomed. 2025 May 7;6(1):27. doi: 10.1186/s43556-025-00267-6.
3
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.
抗CD20抗体疗法对复发缓解型多发性硬化症免疫细胞动力学的影响
Cells. 2025 Apr 6;14(7):552. doi: 10.3390/cells14070552.
4
Alteration and Neurologic Manifestations: A New Family with Large Phenotypic Variability and Literature Review.改变与神经学表现:一个具有大表型变异性的新家族及文献综述
Genes (Basel). 2025 Mar 3;16(3):306. doi: 10.3390/genes16030306.
5
Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis.髓鞘少突胶质细胞糖蛋白(MOG)35-55甘露聚糖缀合物诱导人 T 细胞耐受,可作为多发性硬化症的个体化治疗方法。
Int J Mol Sci. 2024 May 31;25(11):6092. doi: 10.3390/ijms25116092.
6
In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis.计算机分析突出了与继发性进展型多发性硬化症相关的潜在预测指标。
Int J Mol Sci. 2024 Mar 16;25(6):3374. doi: 10.3390/ijms25063374.
7
Treated and Untreated Primary Progressive Multiple Sclerosis: Walkthrough Immunological Changes of Monocytes and T Regulatory Cells.治疗与未治疗的原发性进行性多发性硬化症:单核细胞和调节性T细胞的免疫变化历程
Biomedicines. 2024 Feb 19;12(2):464. doi: 10.3390/biomedicines12020464.
8
Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review.高效多发性硬化症疾病修正药物对免疫突触的影响:一项系统评价
Curr Pharm Des. 2024;30(7):536-551. doi: 10.2174/0113816128288102240131053205.
9
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.免疫检查点为基础的免疫疗法在多发性硬化中的进展:原理与实践。
Cell Commun Signal. 2023 Nov 9;21(1):321. doi: 10.1186/s12964-023-01289-9.
10
Current understanding of CTLA-4: from mechanism to autoimmune diseases.CTLA-4 的现有认识:从机制到自身免疫性疾病。
Front Immunol. 2023 Jul 11;14:1198365. doi: 10.3389/fimmu.2023.1198365. eCollection 2023.